                                 CODE OF VIRGINIA

SCHEDULE V (§ 54.1-3454)

The controlled substances listed in this section are included in Schedule V:

1. Any compound, mixture, or preparation containing limited quantities of any of
the following narcotic drugs, which also contains one or more nonnarcotic active
medicinal ingredients in sufficient proportion to confer upon the compound,
mixture, or preparation, valuable medicinal qualities other than those possessed
by the narcotic drug alone:
			Not more than 200 milligrams of codeine, or any of its salts, per 100
milliliters or per 100 grams;			Not more than 100 milligrams of dihydrocodeine,
or any of its salts, per 100 milliliters or per 100 grams;			Not more than 100
milligrams of ethylmorphine, or any of its salts, per 100 milliliters or per 100
grams;			Not more than 2.5 milligrams of diphenoxylate and not less than 25
micrograms of atropine sulfate per dosage unit;			Not more than 100 milligrams
of opium per 100 milliliters or per 100 grams;			Not more than 0.5 milligrams of
difenoxin and not less than 25 micrograms of atropine sulfate per dosage
unit.			The Board may except by regulation any compound, mixture, or preparation
containing any depressant substance listed in subdivision 1 from the application
of all or any part of this chapter and such substances so excepted may be
dispensed pursuant to &#xA7; 54.1-3416.

2. Unless specifically excepted or listed in another schedule, any material,
compound, mixture, or preparation that contains any quantity of the following
substances having a stimulant effect on the central nervous system, including
its salts, isomers, and salts of isomers:
			Pyrovalerone.

3. Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation that contains any quantity of the
following substances having a depressant effect on the central nervous system,
including its salts:
			Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also
referred to as BRV; UCB-34714; Briviact);			Ezogabine
[N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl
ester]-2779;			Gabapentin [1-(aminomethyl)cyclohexaneacetic
acid];			Ganaxolone;			Lacosamide
[(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];			Lasmiditan
[2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide];		
	Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].

HISTORY: 1972, c. 798, § 54-524.84:12; 1976, c. 614; 1977, c. 302; 1979, c.
387; 1984, c. 186; 1986, c. 463; 1988, c. 765; 1992, c. 737; 1994, c. 763; 2003,
c. 640; 2006, c. 346; 2010, c. 423; 2012, c. 541; 2017, c. 612; 2019, c. 214;
2022, cc. 114, 115; 2024, cc. 62, 228.